Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05669625 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

StatusUnknown
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 18, 2023 (before its estimated April 14, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2023); last known: Active, Not Recruiting
  2. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 1 to 13
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Secondary endpoints: details revised at 2 of 8 entries
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.
Trial Details
NCT Number NCT05669625
Lead Sponsor China National Biotec Group Company Limited
Collaborators: Beijing Institute of Biological Products Co Ltd., Jiangsu Province Centers for Disease Control and Prevention
Conditions
(from sponsor)		 Varicella
Related terms Chickenpox
Enrollment 12,440 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov